| License: Creative Commons Attribution Non-commercial No Derivatives 4.0 PDF - Published Version (740kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-446843
- DOI to cite this document:
- 10.5283/epub.44684
This publication is part of the DEAL contract with Wiley.
Abstract
The overriding goal of adoptive cell therapy with chimeric antigen receptor (CAR) redirected T cells in oncology is to eliminate cancer cells from infiltrated tissues. Clinical trials document that this form of immunotherapy can induce lasting remissions of hematologic malignancies; however, the successes could not yet be transferred to the treatment of solid tumors. In this situation, modulating ...
Owner only: item control page